Is SOLENO THERAPEUTICS INC (SLNO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.5% / 30% | 13.7% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 2.5% / 33% | 13.7% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 16.0% / 33% | 88.1% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 2.5% / 33% | 13.7% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 16.0% / 33% | 88.1% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 98.6% | |
| Operating Margin | 44.1% | |
| Net Margin | 11.0% | |
| Return on Equity (ROE) | 6.0% | |
| Return on Assets (ROA) | 2.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $47M |
| Free Cash Flow | $47M |
| Total Debt | $53M |
| Debt-to-Equity | 11.7 |
| Current Ratio | 5.8 |
| Total Assets | $564M |
Price & Trading
| Last Close | $31.83 |
| 50-Day MA | $38.61 |
| 200-Day MA | $58.19 |
| Avg Volume | 1.6M |
| Beta | -3.0 |
|
52-Week Range
$29.43
| |
About SOLENO THERAPEUTICS INC (SLNO)
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is SOLENO THERAPEUTICS INC (SLNO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), SOLENO THERAPEUTICS INC is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is SOLENO THERAPEUTICS INC's debt ratio?
SOLENO THERAPEUTICS INC's debt ratio is 2.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 16.0%.
What are SOLENO THERAPEUTICS INC's key financial metrics?
SOLENO THERAPEUTICS INC has a market capitalization of $1.6B, trailing P/E ratio of 77.1, and revenue of $190M. The company maintains a gross margin of 98.6% and a net margin of 11.0%. Return on equity stands at 6.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.